Renal functional decline after radical nephrectomy strongly associated with age
December 2nd 2022“We showed that in the oldest patient cohorts, age became an independent risk factor for development of de novo CKD after surgical intervention in patients who underwent radical nephrectomy," says Mimi Vu Nguyen.
Can theranostics improve outcomes in high-risk localized prostate cancer?
December 1st 2022Standard treatment is insufficient for some patients with high-risk localized prostate cancer, and the emerging field of theranostics provides a potential opportunity to improve outcomes, said Karen Elizabeth Hoffman, MD, MHSc, MPH.
Genentech withdraws atezolizumab frontline indication for metastatic urothelial carcinoma
November 29th 2022The confirmatory phase 3 IMvigor130 trial did not show an overall survival advantage with frontline atezolizumab plus chemotherapy vs chemotherapy alone in patients with advanced urothelial carcinoma.
Darolutamide now available in England for mHSPC
November 29th 2022Approval of the treatment was based on the placebo-controlled phase 3 ARASENS trial, which showed that adding darolutamide to standard ADT and docetaxel boosted overall survival versus ADT/docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.
Novel biomarker emerges for salvage RT approach in biochemically recurrent prostate cancer
November 11th 2022A higher score on PORTOS, an expression signature of 24 DNA damage repair and immune pathway genes, predicted improved response to dose-intensified salvage radiotherapy after radical prostatectomy in patients with biochemically recurrent prostate cancer.
Talazoparib/enzalutamide improves rPFS in mCRPC, regardless of HRR gene mutation status
October 4th 2022The talazoparib/enzalutamide combination was also shown to have benefits in key secondary end points, including prostate specific antigen (PSA) response, time to PSA progression, and overall response rate.
Rucaparib delays disease progression in subgroup of chemotherapy-naïve mCRPC
October 4th 2022“Men with this type of metastatic prostate cancer want to get their genetically targeted therapy as early as possible, and this trial clearly shows the value of rucaparib as a treatment for these men,” said Alan H. Bryce, MD, principal investigator of the TRITON3 trial.
Botox, sacral nerve stimulation highlighted as emerging OAB treatments for elderly patients
September 15th 2022Two studies shared at the 2022 Annual Meeting of the South Central Section of the AUA highlighted onabotulinumtoxinA and sacral nerve stimulation as alternative treatment options for patients older than 70 years with overactive bladder.
Stereotactic ablative radiation effective in systemic therapy–naïve oligometastatic kidney cancer
August 23rd 2022“There has never been a clinical trial for these patients. It is unclear whether these patients should be treated with medication, surgery, or another approach. This represents an unmet medical need,” said Raquibul Hannan, MD, PhD.